Literature DB >> 16639624

Lupus nephritis in Chinese children--a territory-wide cohort study in Hong Kong.

Sik-Nin Wong1, Kei-Chiu Tse, Tsz-Leung Lee, Kwok-Wai Lee, Stella Chim, Kwok-Piu Lee, Reann Wai-Po Chu, Winnie Chan, Kwok-Wah Fong, Joannie Hui, Samantha Po-Siu Li, Pa-Shing Yeung, So-Fun Yuen, Assunta Chi-Hang Ho, Lettie Chuk-Kwan Leung, David Luk, Pak-Chiu Tong, Shu-Yan Chan, Hon-Ming Cheung, Chung-Mo Chow, David Lau.   

Abstract

We report a multicenter study of Chinese children in Hong Kong with systemic lupus erythematosus (SLE) nephritis. Children were included if: they fulfilled the ACR criteria, had significant proteinuria or casturia, were Chinese and younger than 19 years and had been diagnosed with SLE between January 1990 and December 2003. Investigators in each center retrieved data on clinical features, biopsy reports, treatment and outcome of these patients. There were 128 patients (eight boys, 120 girls; mean age: 11.9+/-2.8 years). About 50% presented with multisystem illness and 40% with nephritic/nephrotic symptoms. Negative anti-dsDNA antibodies were found in 6% of the patients. Renal biopsy revealed WHO Class II, III, IV and V nephritis in 13 (10%), 22 (17%), 69 (54%) and 13 (10%) patients, respectively. The clinical severity of the nephritis did not accurately predict renal biopsy findings. The follow-up period ranged from 1 to 16.5 years (mean+/-SD: 5.76+/-3.61 years). During the study five patients died (two from lupus flare, one from cardiomyopathy, two from infections). Four patients had endstage renal failure (ESRF) (one died during a lupus flare). All deaths and end-stage renal failure occurred in the Class IV nephritis group. Chronic organ damage was infrequent in the survivors. The actuarial patient survival rates at 5, 10 and 15 years of age were 95.3, 91.8, and 91.8%, respectively. For Class IV nephritis patients, the survival rates without ESRF at 5, 10, and 15 years were 91.5, 82.3 and 76%, respectively. The survival and chronic morbidity rates of the Chinese SLE children in the present study are comparable to those of other published studies.

Entities:  

Mesh:

Year:  2006        PMID: 16639624     DOI: 10.1007/s00467-006-0052-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  30 in total

Review 1.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

2.  Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage.

Authors:  Hermine I Brunner; Earl D Silverman; Theresa To; Claire Bombardier; Brian M Feldman
Journal:  Arthritis Rheum       Date:  2002-02

Review 3.  Treatment of lupus nephritis in children.

Authors:  P Niaudet
Journal:  Pediatr Nephrol       Date:  2000-02       Impact factor: 3.714

4.  Childhood-onset Systemic Lupus Erythematosus: clinical presentation and prognosis in 31 patients.

Authors:  M J Rood; R ten Cate; L W van Suijlekom-Smit; E J den Ouden; F E Ouwerkerk; F C Breedveld; T W Huizinga
Journal:  Scand J Rheumatol       Date:  1999       Impact factor: 3.641

5.  Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome.

Authors:  C C Mok; R W Wong; C S Lau
Journal:  Am J Kidney Dis       Date:  1999-08       Impact factor: 8.860

6.  Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood.

Authors:  H I Brunner; M Freedman; E D Silverman
Journal:  Arthritis Rheum       Date:  1999-11

7.  Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus.

Authors:  Paivi M Miettunen; Oliva Ortiz-Alvarez; Ross E Petty; Rolando Cimaz; Peter N Malleson; David A Cabral; Stephanie Ensworth; Lori B Tucker
Journal:  J Rheumatol       Date:  2004-08       Impact factor: 4.666

8.  Lupus nephritis: prognostic factors in children.

Authors:  D K McCurdy; T J Lehman; B Bernstein; V Hanson; K K King; R Nadorra; B H Landing
Journal:  Pediatrics       Date:  1992-02       Impact factor: 7.124

Review 9.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

10.  Lupus nephritis in children: a longitudinal study of prognostic factors and therapy.

Authors:  N Baqi; S Moazami; A Singh; H Ahmad; S Balachandra; A Tejani
Journal:  J Am Soc Nephrol       Date:  1996-06       Impact factor: 10.121

View more
  14 in total

Review 1.  Prevalence and burden of pediatric-onset systemic lupus erythematosus.

Authors:  Sylvia Kamphuis; Earl D Silverman
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

2.  Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis.

Authors:  C P Lin; I Adrianto; C J Lessard; J A Kelly; K M Kaufman; J M Guthridge; B I Freedman; J-M Anaya; M E Alarcón-Riquelme; B A Pons-Estel; J Martin; S Glenn; A Adler; S-C Bae; S-Y Park; S-Y Bang; Y-W Song; S A Boackle; E E Brown; J C Edberg; G S Alarcón; M A Petri; L A Criswell; R Ramsey-Goldman; J D Reveille; L M Vila; G S Gilkeson; D L Kamen; J Ziegler; C O Jacob; A Rasmussen; J A James; R P Kimberly; J T Merrill; T B Niewold; R H Scofield; A M Stevens; B P Tsao; T J Vyse; C D Langefeld; K L Moser; J B Harley; P M Gaffney; C G Montgomery
Journal:  Genes Immun       Date:  2011-12-22       Impact factor: 2.676

3.  Renal involvement in childhood-onset systemic lupus erythematosus in Egypt.

Authors:  Samia Salah-El-Din Mahmoud; Hafez Mahmoud Bazaraa; Hala Mohamed Lotfy; Doaa Mohamed Abd-El-Aziz
Journal:  Rheumatol Int       Date:  2010-07-24       Impact factor: 2.631

Review 4.  Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics.

Authors:  Guo-Xiang Hao; Lin-Lin Song; Dong-Feng Zhang; Le-Qun Su; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2020-01-14       Impact factor: 4.335

5.  Long-term renal outcomes of childhood-onset global and segmental diffuse proliferative lupus nephritis.

Authors:  Pornpimol Rianthavorn; Athitaya Buddhasri
Journal:  Pediatr Nephrol       Date:  2015-06-09       Impact factor: 3.714

6.  Lupus nephritis in Egyptian children: a 16-year experience.

Authors:  Atef Elmougy; Amr Sarhan; Ayman Hammad; Ahmed El-Refaey; Mohammed Zedan; Riham Eid; Wafaa Laimon; Wafaa Limon; Ashraf Abd Elrahman; Fatma Elhussieni; Enas El-Sherbeny; Ashraf Bakr
Journal:  J Nephrol       Date:  2014-12-10       Impact factor: 3.902

7.  Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus.

Authors:  Wanling Yang; Nan Shen; Dong-Qing Ye; Qiji Liu; Yan Zhang; Xiao-Xia Qian; Nattiya Hirankarn; Dingge Ying; Hai-Feng Pan; Chi Chiu Mok; Tak Mao Chan; Raymond Woon Sing Wong; Ka Wing Lee; Mo Yin Mok; Sik Nin Wong; Alexander Moon Ho Leung; Xiang-Pei Li; Yingyos Avihingsanon; Chun-Ming Wong; Tsz Leung Lee; Marco Hok Kung Ho; Pamela Pui Wah Lee; Yuk Kwan Chang; Philip H Li; Ruo-Jie Li; Lu Zhang; Wilfred Hing Sang Wong; Irene Oi Lin Ng; Chak Sing Lau; Pak Chung Sham; Yu Lung Lau
Journal:  PLoS Genet       Date:  2010-02-12       Impact factor: 5.917

8.  Childhood-onset systemic lupus erythematosus.

Authors:  Wasiu Olowu
Journal:  J Natl Med Assoc       Date:  2007-07       Impact factor: 1.798

9.  The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis.

Authors:  Esra Baskin; Seza Ozen; Nilgun Cakar; Umut S Bayrakci; Erkan Demirkaya; Aysin Bakkaloglu
Journal:  Pediatr Nephrol       Date:  2009-09-01       Impact factor: 3.714

10.  Childhood lupus nephritis: 12 years of experience from a developing country's perspective.

Authors:  Moumita Samanta; Madhumita Nandi; Rakesh Mondal; Avijit Hazra; Sumatra Sarkar; Tapas Sabui; Chanchal Kumar Kundu; Arnab Biswas
Journal:  Eur J Rheumatol       Date:  2017-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.